Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

41. Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients Full Text available with Trip Pro

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients 1) review benefits and risks of cannabis use, with emphasis on otolaryngic disease processes; 2) define and review the endocannabinoid signaling system (ESS); and 3) review state and federal regulations for the use and research of cannabis and ESS modulators.This manuscript is a review of the current literature relevant to the stated objectives.Cannabis (marijuana) use is increasing (...) . It is the most widely used illicit substance in the world. There is increasing interest in its therapeutic potential due to changing perceptions, new research, and legislation changes controlling its use. The legal classification of cannabis is complicated due to varied and conflicting state and federal laws. There are currently two synthetic cannabinoid drugs that are FDA approved. Current indications for use include chemotherapy-related nausea and vomiting, cachexia, and appetite loss. Research has

2018 Laryngoscope investigative otolaryngology

42. Simplified guideline for prescribing medical cannabinoids in primary care

-If considering medical cannabinoids, we recommend against medical marijuana (particularly smoked) as the initial product (strong recommendation) — Evidence for smoked cannabis has a very high risk of bias, and long-term consequences are unknown — Products available can have far higher concentrations of THC and CBD than those researched Management of nausea and vomiting • General: We recommend against use of medical cannabinoids for general nausea and vomiting owing to the lack of evidence and known harms (...) effects of cannabis and cannabinoids. The current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017. 7. Lake S, Kerr T, Montaner J. Prescribing medical cannabis in Canada: are we being too cautious? Can J Public Health 2015;106(5):e328-30. 8. Vogel L. Cautious first guidance for prescribing pot. CMAJ 2014;186(16):E595. 9. St-Amant H, Ware MA, Julien N, Lacasse A. Prevalence and determinants of cannabi- noid prescription for the management of chronic

2018 CPG Infobase

43. What effects -- if any -- does marijuana use during pregnancy have on the fetus or child?

What effects -- if any -- does marijuana use during pregnancy have on the fetus or child? What effects -- if any -- does marijuana use during pregnancy have on the fetus or child? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What effects -- if any -- does marijuana use during pregnancy have on the fetus or child (...) ? View/ Open Date 2017 Format Metadata Abstract What effects -- if any -- does marijuana use during pregnancy have on the fetus or child? Evidence-based answer: The effects are unclear. Marijuana use during pregnancy is associated with clinically unimportant lower birth weights (growth differences of approximately 100 g), but no differences in preterm births or congenital anomalies (strength of recommendation [SOR]: B, prospective and retrospective cohort studies with methodologic flaws). Similarly

2018 Clinical Inquiries

44. Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

randomized cross-over trials, despite better reporting, contribute little to the evidentiary base as they were small, exploratory safety sub-studies of short-term treatment exposure to a formulation of THC unavailable in Canada. Thus, there remains a gap in the evidence on the use of cannabinoids in the treatment of dementia, which currently makes evidence-informed decision-making challenging. Tags dementia, geriatrics, nervous system, aggression, behavior, cannabinoids, alzheimer, Nabilone, Cannabis (...) Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

45. Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

randomized cross-over trials, despite better reporting, contribute little to the evidentiary base as they were small, exploratory safety sub-studies of short-term treatment exposure to a formulation of THC unavailable in Canada. Thus, there remains a gap in the evidence on the use of cannabinoids in the treatment of dementia, which currently makes evidence-informed decision-making challenging. Tags dementia, geriatrics, nervous system, aggression, behavior, cannabinoids, alzheimer, Nabilone, Cannabis (...) Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines

Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Last updated: September 10, 2018 Project Number: RB1257-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of medical cannabis products for symptom control in adult palliative care patients? What are the evidence-based guidelines regarding medical cannabis products for symptom control in adult palliative care patients? Key Message Two systematic reviews (one with a meta-analysis), one non-randomized study, and two evidence-based guidelines were identified regarding medical cannabis products for symptom control in adult palliative care patients. Files

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

47. Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment: ? Katharina Overlack ? Ulrich Grouven ? Petra Kohlepp ? Ulrike Lampert ? Min Ripoll ? Cornelia Rüdig ? Sonja Schiller ? Volker Vervölgyi Keywords: cannabinoids, multiple sclerosis, benefit assessment, NCT00681538 Extract of dossier assessment A18-27 Version 1.0 Extract from Cannabis sativa (spasticity due (...) Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Extrakt aus Cannabis sativa (Spastik aufgrund von multipler Sklerose) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 26 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

48. Faculty Position Statement on the medicinal use of Cannabinoids in Pain Medicine

Faculty Position Statement on the medicinal use of Cannabinoids in Pain Medicine Faculty Position Statement on the medicinal use of Cannabinoids in Pain Medicine This statement is focused on the issues relating to cannabis derived medicinal products in relation to Pain Medicine. It does not comment on other areas of medical practice or recreational use, which lie outside our remit. The issue of cannabis, its extracts, formulations and synthetics has very much been on the radar of pain medicine (...) for many years. The Cochrane review 1 in March 2018 concluded, “There is a lack of good evidence that any cannabis- derived product works for any chronic neuropathic pain.” The authors also concluded that “The potential benefits of cannabis-based medicine in chronic neuropathic pain might be outweighed by their potential harms.” The latest review in Pain 2 also concluded “It appears unlikely that cannabinoids are highly effective medicines for Chronic non-cancer pain.” It is important to note that both

2018 Faculty of Pain Medicine

49. Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009–2016 Full Text available with Trip Pro

Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009–2016 29279917 2018 01 08 2018 11 13 1538-3598 318 24 2017 12 26 JAMA JAMA Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009-2016. 2490-2491 10.1001/jama.2017.17225 Young-Wolff Kelly C KC Division of Research, Kaiser Permanente Northern California, Oakland. Tucker Lue-Yen LY Division of Research, Kaiser Permanente Northern (...) Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA 7501160 0098-7484 AIM IM Adolescent Adult California Female Humans Marijuana Use trends Pregnancy Self Report Substance Abuse Detection Young Adult 2017 12 28 6 0 2017 12 28 6 0 2018 1 9 6 0 ppublish 29279917 2667052 10.1001/jama.2017.17225 PMC5769923 NIHMS931325 Am J Obstet Gynecol. 2015 Aug;213(2):201.e1-201.e10 25772211 Biol Psychiatry. 2016 Apr 1;79(7):613-9 26903403 JAMA. 2017 Jan 10;317(2):207-209

2017 JAMA

50. Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines

is the clinical effectiveness on the use of medical cannabis in the elderly? What are the evidence-based guidelines on the use of medical cannabis in the elderly? Key Message One systematic review, four randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness on the use of medical cannabis in the elderly. Tags geriatrics, aged, cannabinoids, cannabis, marijuana abuse, older adult, Elderly Files Rapid Response Reference List Published : December 21, 2017 (...) Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Published on: December 21, 2017 Project Number: RA0944-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Cereal progenitors differ in stand harvest characteristics from related wild grasses Full Text available with Trip Pro

Cereal progenitors differ in stand harvest characteristics from related wild grasses The domestication of crops in the Fertile Crescent began approximately 10,000 years ago indicating a change from a hunter-gatherer lifestyle to a sedentary, agriculture-based existence. The exploitation of wild plants changed during this transition, such that a small number of crops were domesticated from the broader range of species gathered from the wild. However, the reasons for this change (...) are unclear.Previous studies have shown unexpectedly that crop progenitors are not consistently higher yielding than related wild grass species, when growing without competition. In this study, we replicate more closely natural competition within wild stands, using two greenhouse experiments to investigate whether cereal progenitors exhibit a greater seed yield per unit area than related wild species that were not domesticated.Stands of cereal progenitors do not provide a greater total seed yield per unit ground

2017 The Journal of ecology

52. Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use

is currently the world’s most used illicit psychoactive substance, with 2012 estimates showing that about 200 million people globally reported using it at least once. • In 2013, despite having been prohibited since the 1920s, Canada had the highest rate of marijuana use among youth for all developed nations. • The prosecution and enforcement of cannabis laws is resource intensive, and the results of these charges have serious implications for the individuals who are prosecuted, especially for young adults (...) of research evidence We identified research evidence (systematic reviews and primary studies) by searching (in April 2017) in PubMed, Health Systems Evidence, JSTOR, and Social Science Abstracts, using the search strategy: (cannabis OR marijuana) AND (legal OR legalization OR decriminalization). In all of the databases we limited our search to the past 10 years. For the second question, we conducted a jurisdictional scan using grey literature from the Canadian Task Force for the Legalization, Regulation

2017 McMaster Health Forum

53. Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines

regarding the clinical effectiveness of integrated cessation programs in adults who smoke cannabis and tobacco. Tags cannabinoids, cannabis, endocannabinoids, marijuana abuse, marijuana smoking, nicotine, receptors, cannabinoid, smoking, smoking cessation, tobacco, tobacco use cessation products, tobacco use disorder, addiction, other miscellaneous topics, Cigarette, Cigarettes, marihuana, marijuana, Cannabinoid, tetrahydrocannabinoid, quitting, quitting smoking, Reduce, reduction, discontinue (...) Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Published

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

54. Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

trials were identified regarding pharmacological interventions for cannabis use disorder. Tags acetylcysteine, buspirone, cannabidiol, cannabis, marijuana abuse, marijuana smoking, addiction, other miscellaneous topics, marijuana, marihuana, switching, Addiction, addictions, substance abuse, substance use, substance use disorder, substance use disorders, reduction, prevent, preventative Files Rapid Response Reference List Published : September 22, 2017 Related Content Follow us: © 2019 Canadian (...) Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

55. Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

for the prevention or treatment of cannabis use in adults? Key Message Five systematic reviews, one meta-analysis, seven randomized controlled trials, and one evidence-based guideline were identified regarding psychological and psychosocial interventions for the prevention or treatment of cannabis use in adults. Tags mental health, behavior therapy, cannabinoids, cannabis, family therapy, marijuana abuse, marijuana smoking, mind-body therapies, psychotherapy, other miscellaneous topics, marihuana, marijuana (...) Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

56. Recreational marijuana legalization and college student use: Early evidence Full Text available with Trip Pro

Recreational marijuana legalization and college student use: Early evidence We analyze marijuana use by college undergraduates before and after legalization of recreational marijuana. Using survey data from the National College Health Assessment, we show that students at Washington State University experienced a significant increase in marijuana use after legalization. This increase is larger than would be predicted by national trends. The change is strongest among females, Black students

2017 SSM - population health

57. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations Full Text available with Trip Pro

the age of 16 years), (3) choose low-potency tetrahydrocannabinol (THC) or balanced THC-to-cannabidiol (CBD)-ratio cannabis products, (4) abstain from using synthetic cannabinoids, (5) avoid combusted cannabis inhalation and give preference to nonsmoking use methods, (6) avoid deep or other risky inhalation practices, (7) avoid high-frequency (e.g., daily or near-daily) cannabis use, (8) abstain from cannabis-impaired driving, (9) populations at higher risk for cannabis use-related health problems (...) Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors

2017 EvidenceUpdates

58. Severity and outcomes of acute alcoholic pancreatitis in cannabis users Full Text available with Trip Pro

Severity and outcomes of acute alcoholic pancreatitis in cannabis users Cannabis is the most commonly and widely used illicit drug in the world and is also the most commonly used drug of abuse in alcohol drinkers. Experimental studies have shown conflicting results of the effects of cannabis on the severity of acute pancreatitis (AP). The purpose of this study is to ascertain the clinical effects of simultaneous alcohol and cannabis use on severity at presentation and outcomes of acute (...) alcoholic pancreatitis (AAP).A retrospective review was conducted on the patients discharged with principle or secondary diagnosis of AP using ICD-9 & ICD-10 codes during the time period from January 2006 to December 2015 at a large community-based hospital in Central Georgia. Patients with alcoholic pancreatitis with cannabis (CB+) and without cannabis (CB-) use were identified and were matched with sex and age.Our study findings showed that a greater percentage of CB+ patients did not have a systemic

2017 Translational gastroenterology and hepatology

59. [Cannabinoids in patients with autism spectrum disorders]

[Cannabinoids in patients with autism spectrum disorders] [Cannabinoids in patients with autism spectrum disorders] [Cannabinoids in patients with autism spectrum disorders] Virgilio S, Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Alcaraz (...) A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A. [Cannabinoids in patients with autism spectrum disorders] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 523. 2017 Authors' conclusions No available scientific evidence which would allow determining the effectiveness of cannabinoids use for the treatment of patients with autism spectrum disorders was found

2017 Health Technology Assessment (HTA) Database.

60. Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines

study were identified regarding the use of medical cannabis or cannabinoids in the treatment of insomnia disorder in adults. Tags cannabidiol, cannabinoids, cannabis, insomnia, marihuana, marijuana, mental health, sleep disorders, sleep initiation and maintenance disorders, sleeplessness, Cannabinoid, insomniac, insomniacs, sleep dysfunction Files Rapid Response Summary of Abstracts Published : June 26, 2017 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get (...) Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review